Other Information
−Removed: During the three months ended September 30, 2025, no director or “officer” (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended) adopted or terminated a “Rule 10b5 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as each term is defined in Item 408(a) of Regulation S-K.
+Added: During the three months ended March 31, 2026, no director or “officer” (as defined in Rule 16a-1(f) under the Exchange Act) adopted or terminated a “Rule 10b5 trading arrangement” or “non-Rule 10b5-1 trading arrangement” as each term is defined in Item 408(a) of Regulation S-K.
Second Amended and Restated Certificate of Incorporation of the Company (Incorporated by reference to Exhibit 3.1 to the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2015, filed on August 10, 2015 (File No.
2 unchanged sentences
Certificate of Designation of Series A Convertible Preferred Stock of the Company (Incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K filed June 19, 2020 (File No.
−Removed: Indenture, dated August 27, 2025, between Novavax, Inc.
−Removed: and The Bank of New York Mellon Trust Company, N.A., as Trustee (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed August 27, 2025 (File No.
−Removed: Form of 4.625% Convertible Senior Notes due 2031 (included as Exhibit A to Exhibit 4.1) (Incorporated by reference to Exhibit 4.1 to the Company’s Current Report on Form 8-K filed August 27, 2025 (File No.
Form of Exchange and Subscription Agreement (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed August 21, 2025 (File No.
−Removed: First Amendment to Collaboration and License Agreement between the Company and Sanofi Pasteur Inc., dated July 28, 2025
−Removed: Second Amendment to Collaboration and License Agreement between the Company and Sanofi Pasteur Inc , dated July 28, 2025
−Removed: Assignment and Assumption of Lease b etween the Company and AstraZeneca Pharmaceuticals, LP, dated October 1 7 , 2025 (Incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed October 22 , 2025 (File No.
+Added: 10.1 * ^+
+Added: License Agreement, dated January 14, 2026, by and between the Company and Pfizer, Inc.
+Added: (Incorporated by reference to Exhibit 10.63 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed on February 26, 2026 (File No.
+Added: Credit, Security and Guaranty Agreement, dated as of February 25, 2026, by and among Novavax, Inc., as borrower, the lenders from time to time party thereto and MidCap Financial Trust, as administrative agent (Incorporated by reference to Exhibit 10.64 to the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed on February 26, 2026 (File No.
Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(e) of the Securities Exchange Act
4 unchanged sentences
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
−Removed: 101 The following financial information from our Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, formatted in Inline Extensible Business Reporting Language (Inline XBRL):
−Removed: (i) the Consolidated Statements of Operations for the three and nine-month periods ended September 30, 2025 and 2024, (ii) the Consolidated Statements of Comprehensive Income (Loss) for the three and nine-month periods ended September 30, 2025 and 2024, (iii) the Consolidated Balance Sheets as of September 30, 2025 and December 31, 2024, (iv) the Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the three and nine-month periods ended September 30, 2025 and 2024, (v) the Consolidated Statements of Cash Flows for the nine-month periods ended September 30, 2025 and 2024, and (vi) the Notes to the Consolidated Financial Statements.
+Added: 101 The following financial information from our Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, formatted in Inline Extensible Business Reporting Language (Inline XBRL):
+Added: (i) the Consolidated Statements of Operations for the three-month ended March 31, 2026 and 2025, (ii) the Consolidated Statements of Comprehensive Income (Loss) for the three-month periods ended March 31, 2026 and 2025, (iii) the Consolidated Balance Sheets as of March 31, 2026 and December 31, 2025, (iv) the Consolidated Statements of Changes in Stockholders’ Equity (Deficit) for the three-month ended March 31, 2026 and 2025, (v) the Consolidated Statements of Cash Flows for the three-month ended March 31, 2026 and 2025, and (vi) the Notes to the Consolidated Financial Statements.
104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).
2 unchanged sentences
** Furnished herewith.
−Removed: † Certain portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
−Removed: The Company hereby agrees to furnish supplementally to the SEC, upon its request, an unredacted copy of this exhibit.
+Added: Certain portions of this exhibit (indicated by [***]) have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.
+ Annexes, schedules and/or exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K.
2 unchanged sentences
NOVAVAX, INC.
−Removed: November 6, 2025 By:
+Added: May 6, 2026 By:
President and Chief Executive Officer
(Principal Executive Officer)
−Removed: November 6, 2025 By:
+Added: May 6, 2026 By:
Executive Vice President, Chief Financial Officer and Treasurer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.